Dr. Webster is an Assistant Professor of Oncology at The Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Webster has expertise in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). Dr. Webster received his medical degree from The Stanford University School of Medicine. He completed residency training in internal medicine at Johns Hopkins followed by a fellowship in medical oncology. He completed the Science of Clinical Investigation curriculum at the Johns Hopkins Bloomberg School of Public health. Dr. Webster is a member of the American Society of Hematology, and the American Society of Clinical Oncology. Dr. Webster’s research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of acute leukemias (ALL and AML). He has specific expertise in the use of maintenance therapies following bone marrow transplantation. He has developed novel clinical trials utilizing immunotherapy for the treatment of ALL and the prevention of post-transplant relapse in both ALL and AML. He serves as the Principal Investigator for these trials of post-transplant maintenance strategies, as well as the site PI for multi-center trials that are currently being conducted through the Eastern Co-operative Oncology Group (ECOG)-ACRIN and Experimental Therapeutics Clinical Trials Network (ETCTN). As the leader of the adult ALL program at Johns Hopkins, he has focused on increasing clinical trial enrollments and improving outcomes in adult ALL. Dr. Webster is rated as an Elite provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Patrick Brown is an Oncologist in Baltimore, Maryland. Dr. Brown is rated as an Elite provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, WT1-Related Wilms Tumor Syndromes, Thrombectomy, and Carotid Artery Surgery.

Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program. She has served on the National Cancer Institute (NCI) Investigational Drug Steering Committee since 2014. Dr. Gojo received a Service Star Award from Johns Hopkins Medicine Service Excellence in 2018 for her exemplary care of leukemia patients. Dr. Gojo contributed to the clinical translational and drug development effort of multiple novel agents targeting pathogenic pathways in patients with acute leukemia. Her research efforts are now concentrated on the development and integration of novel immunotherapies into therapeutic armamentarium for patients with acute leukemia. She mentors basic and clinical research fellows and junior faculty on the development and design of novel clinical trials and mechanistic laboratory studies associated with these trials. She served as a leukemia team leader on the National Institute of Health (NIH)/NCI N01 grant (Phase II consortium) (2009-2011), and is co-principal investigator (PI) on the Experimental Therapeutics (ET)-Clinical Trial Network (CTN) UM1 grant supporting early clinical trials. Dr. Gojo has served on the National Comprehensive Cancer Network guideline panel for AML since 2019, Myeloid Growth Factor guideline panel since 2015 and previously served on the MPNs guideline panel (2016-2019). She has extensive experience in the regulatory aspects of drug development and served as the Chair (2015-2016) and Co-Chair (2014-2015) of the Cancer Research Review Committee at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, and serves as a member of the SKCCC Biostatistics Core Advisory Committee and SKCCC Clinical Research Office Coordinating Center Oversight Committee. Dr. Gojo is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Mark J. Levis, M.D., Ph.D., professor of oncology, medicine and pharmacology in the Division of Hematologic Malignancies at the Johns Hopkins University School of Medicine, co-directs the Hematologic Malignancies and Bone Marrow Transplantation Program and directs the Adult Leukemia Service at the Johns Hopkins Sidney Kimmel Cancer Center. In addition to his role within the Kimmel Cancer Center, he serves on the faculty for the Johns Hopkins Graduate Training Program in Cellular and Molecular Medicine, a Ph.D. program that prepares scientists to conduct laboratory research at the cellular and molecular level that is designed to have a direct impact on the understanding of human diseases. Dr. Levis has expertise in acute and chronic myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes. Dr. Levis received his medical degree at the University of California, San Francisco School of Medicine, where he also earned his Ph.D. in Biochemistry. He completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology. Dr. Levis is a member of the American Society of Hematology, the American Society of Clinical Oncology and the European Hematology Association. He is an ad hoc member of the Oncology Drug Advisory Committee, as well as an ad hoc manuscript referee for peer-reviewed journals such as New England Journal of Medicine; Leukemia; Clinical Cancer Research; and The American Journal of Hematology. Dr. Levis has earned numerous awards, such as the Daniel Nathans Research Award from Johns Hopkins University, the Osler Housestaff Teaching Award, the Director's Teaching Award in Clinical Science, and the Advanced Clinical Research Award from the American Society of Clinical Oncology. Dr. Levis’ laboratory research focuses on the development of molecularly-targeted therapies for leukemia. He is actively involved in the pre-clinical and clinical development of small molecule inhibitors of protein kinases, including FLT3. The research involves studying the biochemical effects of these inhibitors on samples taken from leukemia patients, with the broad goal of identifying and validating novel molecular therapeutic targets in these hematopoietic malignancies. While Dr. Levis plays a key role in the pre-clinical development of these therapies, he is particularly interested in translating this research to the bedside of his patients by using correlative studies to incorporate these novel therapies into existing treatments. In addition to his work in both the clinic and the laboratory, Dr. Levis has also conducted talks, mentorship and teaching lectures, and published extensively in the top journals in his field, including Leukemia; Blood; and the New England Journal of Medicine. Dr. Levis is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Maria Baer is a Hematologist in Baltimore, Maryland. Dr. Baer is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Splenectomy.

Dr. Gabrielle Prince is an Oncologist in Baltimore caring for patients with leukemias and other blood and bone marrow disorders. She is viewed regionally as a clinical expert in the care of patients with these disorders and has served as the Principal Investigator for numerous clinical trials studying new treatments for the most challenging clinical cases. Dr. Prince received her undergraduate degree in Biomedical Engineering from Columbia University (New York, NY), earned her M.D. at the State University of New York (Brooklyn, NY), completed her Residency at Columbia University Medical Center-New York Presbyterian (New York, NY), and Fellowship in Medical Oncology at Johns Hopkins (Baltimore, MD). Dr. Prince joined the Johns Hopkins faculty in 2014 at the completion of her training. Her main research interests include drug development for patients with AML, MDS, and MPDs. She has been involved in several clinical trials that helped lead to FDA approval of those new drugs and she remains interested in helping the program maintain a broad-based clinical trials portfolio. Dr. Prince is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Childhood Acute Myeloid Leukemia, and Bone Marrow Aspiration.

Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Philip Imus is an oncologist in the Baltimore area, caring for patients with hematologic malignancies. Dr. Imus received his undergraduate degree (cum laude) in English from Rice University. He earned his M.D. from Columbia University College of Physicians and Surgeons. He completed his residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and performed a fellowship in oncology at Johns Hopkins. Dr. Imus is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy.

Dr. Stacy Cooper is the Director of the Pediatric Hematologic Malignancy Program, Director of the Pediatric Hematology/Oncology Fellowship Program, and Clinical Director of the Pediatric Oncology Inpatient Program at the Johns Hopkins School of Medicine. Dr. Cooper received her undergraduate degree in Biology and Spanish at the University of Notre Dame. She earned her M.D. at SUNY Upstate Medical University. She completed her general pediatric residency and chief residency at the Johns Hopkins School of Medicine. She completed her pediatric hematology-oncology fellowship with the Johns Hopkins-National Institutes of Health. Dr. Cooper joined the Johns Hopkins faculty in 2015. Her research focuses on clinical research in acute lymphoblastic leukemia, as well as medical education scholarship related to fellowship training. Dr. Cooper is a member of the American Board of Pediatrics, the American Society of Hematology, the American Society of Pediatric Hematology Oncology and the Association of Pediatric Program Directors. Dr. Cooper is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Leukemia, and Bone Marrow Transplant.

Yang Ding is a Pediatrics specialist and a Pediatric Hematologist Oncology provider in Baltimore, Maryland. Dr. Ding is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Neuroblastoma, and Langerhans Cell Histiocytosis.

Dr. Majid Khan is a Radiologist and Director, Non-Vascular Spine Intervention at Johns Hopkins University hospitals. Dr. Khan graduated from University of Kashmir, India in 1993. He completed his residency in radiology at the Nassau University Medical Center at Stony Brooks University and then completed his fellowship in Neuroradiology at Johns Hopkins University. Dr. Majid is deeply invested in both diagnostic Neuroradiology with particular emphasis on advanced head & neck and spine tumor imaging. His prime interest is doing spine tumor ablations primarily using microwave ablation devices and has performed the most number of such cases in the United States. He has significant expertise in spine cement augmentation procedures like kyphoplasty and vertebroplasty for treatment of compression fractures due to osteoporosis, multiple myeloma and/or other tumor-associated pathological fractures, sacroplasty for the treatment of fractures of the sacrum, epidural steroid injections, facet and transforaminal nerve blocks. He has treated a considerable number of patients with Tarlov and synovial cysts. Dr. Khan is a core member of Johns Hopkins Headaches and CSF Leak Program doing both targeted and non-targeted blood and fibrin glue patches. In addition, Dr. Khan has performed numerous imaging-guided head and neck biopsies with expertise in deep trans-facial biopsies. Dr. Majid has contributed to numerous publications and book chapters and has given regional, national and international talks, as well as presented research at many national meetings. He is a member of the American Society of Neuroradiology, American College of Radiology, American Society of Spine Radiology, North American Spine Society, Radiologic Society of North America, European Society of Radiology. Dr. Khan is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Cerebrospinal Fluid Leak, Meningocele, Tarlov Cysts, Vertebroplasty, and Bone Graft.

Vu Duong is a Hematologist in Baltimore, Maryland. Dr. Duong is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Myringotomy.

Sandrine Niyongere is a Hematologist in Baltimore, Maryland. Dr. Niyongere is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, and Bone Marrow Aspiration.

Peter Aplan is a Pediatrics specialist and a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Aplan is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Leukemia, Acute Lymphoblastic Leukemia (ALL), and Adult T-Cell Leukemia.

Dr. B. Douglas Smith is an Oncologist in Baltimore caring for patients with leukemias and other blood and bone marrow disorders and he is recognized nationally as an expert in the care of patients with these disorders and as a leader in novel therapeutics for these conditions. Dr. Smith serves as the Co-Director of Clinical Research Operations for the Division of Hematologic Malignancies and helps to manage the Division’s clinical research trials. Dr. Smith received his undergraduate degree in Biology from Lafayette College (Easton, PA), earned his M.D. at the Medical College of Pennsylvania (Philadelphia, PA), completed his Residency at Strong Memorial Hospital of the University of Rochester (Rochester, NY), and Fellowship in Medical Oncology at Johns Hopkins (Baltimore, MD). Dr. Smith joined the Johns Hopkins faculty in 1998 at the completion of his training. His main research interests include drug development for patients with AML, CML, and MDS and he serves as Co-Investigator for the Oncology Center’s UM1 (early phase drug development) Grant. The Leukemia Program’s clinical trials portfolio has included trials for each of the 8 newly FDA-approved drugs for acute leukemia in the past 2 years. Dr. Smith has a passion for teaching trainees and has served on the Fellowship Executive Committee since 2010 focusing on the program’s educational platforms. He has won numerous teaching awards in both the Department of Oncology and the Department of Medicine multiple times, and he has a track record of mentoring fellows pursuing clinical-translational research and clinician-educator pathways. In 2020, Dr. Smith was awarded membership in the prestigious Miller Coulson Academy for Excellence in Clinical Care. He is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American Association for Cancer Research. He has served on the National Comprehensive Cancer Network guideline panel for CML since 2001 and previously served on the AML panel from 2001-2015. Dr. Smith has extensive experience in the regulatory aspects of drug development and he currently serves as the Chair of the Johns Hopkins Institutional Review Board #2. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Childhood Acute Myeloid Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Dr. Alexander J. Ambinder is an instructor of medicine at the Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins. Dr. Ambinder has expertise in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and bone marrow transplantation. Dr. Ambinder received his B.A. from Washington University in St. Louis. He earned his M.D. from Emory University School of Medicine and his M.P.H. from Emory University Rollins School of Public Health. He completed the Osler Medical Residency Training Program in internal medicine at Johns Hopkins and subsequently served as an Assistant Chief of Service (Chief Resident). He completed his fellowships in Hematology and Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and also served as a Chief Fellow. Dr. Ambinder is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Ambinder’s principle research interest is in designing and conducting clinical trials inspired by laboratory insights to improve the management of acute myeloid leukemia and myelodysplastic syndrome. He also has an interest in building large databases that will yield insights that allow for more personalized approaches to the care and treatment of patients with blood cancers. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

"Chen's primary area of research focuses on bone marrow transplantation (BMT), a highly complex and specialized aspect of pediatric oncology that, in recent years, has become an accepted form of therapy for an increasingly broad range of cancers. In addition to the myriad ways BMT is currently being utilized at Hopkins, Chen is working to refine novel approaches to the therapy and apply them to some of the toughest cases. ""One hypothesis is that, in patients receiving a transplant using their own stored stem cells, we can induce an immunologic response from their own cells that mimics the graft received from a healthy donor,"" Chen says. ""We're also excited about the ability to foster immune tolerance when the only available healthy donors aren't perfect matches for the patient."" In a quest to solve some of the rarest and most troubling treatment challenges facing pediatric oncology, Chen and fellow pediatric oncologists at Hopkins have joined forces with others around North America in the Pediatric Blood and Marrow Transplant Consortium. ""We're trying to develop multi-institutional studies to improve the effectiveness of BMT for cancer. The study we're working on now will help us to understand why some patients relapse in spite of BMT for acute myeloid leukemia,"" says Chen, who chairs the Oncology Strategy Group of this consortium. Chen also immerses himself in several Hopkins-based initiatives. Recently, he was named Chair of the Oncology Clinical Research Review Committee, a group mandated to oversee all patient-oriented research in the comprehensive cancer center to ensure it meets the center's standards of scientific merit and priority. He also chairs the Performance Improvement Committee. This multi-disciplinary group consists of physicians, nurses, and pharmacists who examine practical ways to reduce errors and improve patient outcomes. The committee recently joined forces with Hopkins' information technology professionals to apply a computerized order entry system—even to complex treatment protocols like chemotherapy. ""We've seen an amazing improvement; a number of potential medication errors decreased dramatically,"" Chen says. Currently, the committee is analyzing ways to reduce bloodstream infections in pediatric patients, which can create potentially life-threatening complications. Despite the hectic pace of Chen's professional life, he has managed to find a way to leave behind the stress of his job and bond with his own children. He and his sons began taking Kung Fu classes when his older son began middle school. He's since grown up and left for college, but Chen continues the practice as both a student and a teacher. Regardless of where Chen is, he's never too far removed from the challenges that await him at work. ""Sometimes, in the wee hours of the morning, I suddenly realize why a complication has occurred,"" he says.". Dr. Chen is rated as an Experienced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Ganglioneuroblastoma, Leukemia, and Neuroblastoma.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.